Effects of Rimonabant on Liver Fat, Visceral Adipose Tissue Mass and early Markers of CardioDiabetes in obese Subjects with the Metabolic Syndrome- a randomized, double-blind clinical trial.
Phase of Trial: Phase IV
Latest Information Update: 31 Oct 2011
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity; Overweight
- Focus Biomarker; Therapeutic Use
- 25 Jul 2011 New trial record